伊布替尼联合复方黄黛片治疗复发难治性霍奇金淋巴瘤1例并文献复习
Ibrutinib Combined with Compound Realgar Natural Indigo Tablets for the Treatment of Relapsed and Refractory Hodgkin Lymphoma: A Case Report and Literature Review
摘要: 目的：探讨伊布替尼联合复方黄黛片治疗复发难治性霍奇金淋巴瘤患者的疗效及预后。方法：回顾性分析1例伊布替尼联合复方黄黛片治疗自体干细胞移植后复发难治性霍奇金淋巴瘤患者的疗效，并结合相关文献报道，分析其相关机制及潜在应用价值。结果：该例患者接受治疗后病情稳定达15个月，生存期显著延长。结论：伊布替尼和复方黄黛片两药可能有协同抑制淋巴瘤细胞增殖、促进细胞凋亡和阻滞细胞周期的作用，为复发难治霍奇金淋巴瘤提供了新的治疗思路。
Abstract: Objective: To investigate the efficacy and prognosis of ibrutinib combined with Compound Realgar Natural Indigo Tablets (CRNIT) for the patients with relapsed and refractory Hodgkin lymphoma. Methods: The efficacy of ibrutinib combined with CRNIT for a patient with relapsed and refractory Hodgkin lymphoma after autologous stem cell transplantation was retrospectively analyzed. The related mechanism and potential application value of ibrutinib combined with CRNIT were ana-lyzed according to relevant literature reports. Results: The patient remained stable for 15 months by this treatment regimen, and the survival time was significantly prolonged. Conclusion: Ibrutinib and CRNIT may synergistically inhibit the proliferation of lymphoma cells, promote cell apoptosis and cell cycle arrest, which provides a new therapeutic idea for relapsed and refractory Hodgkin lymphoma.
文章引用：丰雨, 刘珊珊, 聂淑敏, 李田兰, 周静静, 毛春霞, 黄俊霞, 高燕, 李硕, 冯献启. 伊布替尼联合复方黄黛片治疗复发难治性霍奇金淋巴瘤1例并文献复习[J]. 临床医学进展, 2024, 14(1): 834-838. https://doi.org/10.12677/ACM.2024.141117

参考文献

[1] 金栋材, 赵丽. 复发/难治性霍奇金淋巴瘤治疗策略的研究进展[J]. 中国实验血液学杂志, 2020, 28(1): 343-349.
[2] Ansell, S.M. (2018) Hodgkin Lymphoma: 2018 Update on Diagnosis, Risk-Stratification, and Manage-ment. American Journal of Hematology, 93, 704-715. [Google Scholar] [CrossRef] [PubMed]
[3] Timothy, J.V. and Beaven, A.W. (2020) Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers, 12, 2887. [Google Scholar] [CrossRef] [PubMed]
[4] Hamadani, M., Balasubramanian, S. and Hari, P.N. (2015) Ibrutinibin Refractory Classic Hodgkin’s Lymphoma. The New England Journal of Medicine, 373, 1381-1382. [Google Scholar] [CrossRef] 
[5] Du, J., Neuenschwander, M., Yu. Y., et al. (2017) Pharmacological Restoration and Therapeutic Targeting of the B-Cell Phenotype in Classical Hodgkin Lymphoma. Blood, 129, 71-81. [Google Scholar] [CrossRef] [PubMed]
[6] 王金妮, 刘爱春. 晚期经典型霍奇金淋巴瘤的治疗进展[J]. 现代肿瘤医学, 2021, 29(4): 688-692.
[7] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会和中国霍奇金淋巴瘤工作组. 中国霍奇金淋巴瘤的诊断与治疗指南(2022年版) [J]. 中华血液学杂志, 2022, 43(9): 705-715.
[8] Ullah, F., Dima, D., Omar, N., et al. (2023) Advances in the Treatment of Hodgkin Lymphoma: Current and Future Approaches. Frontiers in Oncology, 13, Article ID: 1067289. [Google Scholar] [CrossRef] [PubMed]
[9] Dong, R., Yan, Y., Zeng, X., et al. (2022) Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Design, Development and Therapy, 16, 3225-3239. [Google Scholar] [CrossRef] 
[10] Alu, A., Lei, H., Han, X., et al. (2022) BTK Inhibitors in the Treat-ment of Hematological Malignancies and Inflammatory Diseases: Mechanisms and Clinical Studies. Journal of Hema-tology & Oncology, 15, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[11] Balaji, S., Ahmed, M., Lorence, E., et al. (2018) NF-κB Signal-ing and Its Relevance to the Treatment of Mantle Cell Lymphoma. Journal of Hematology & Oncology, 11, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[12] Pan, Z., Scheerens, H., Li, S.-J., et al. (2007) Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. ChemMedChem, 2, 58-61. [Google Scholar] [CrossRef] [PubMed]
[13] Fernández-Vega, I., Quirós, L.M., Santos-Juanes, J., Pane-Foix, M. and Marafioti, T. (2015) Bruton’s Tyrosine Kinase (Btk) Is a Useful Marker for Hodgkin and B Cell Non-Hodgkin Lymphoma. Virchows Archiv: An International Journal of Pathology, 466, 229-235. [Google Scholar] [CrossRef] [PubMed]
[14] Brown, J.R. (2013) Ibrutinib (PCI-32765), the First BTK (Bru-ton’s Tyrosine Kinase) Inhibitor in Clinical Trials. Current Hematologic Malignancy Reports, 8, 1-6. [Google Scholar] [CrossRef] [PubMed]
[15] Ran, F., Liu, Y., Wang, C., et al. (2022) Review of the Develop-ment of BTK Inhibitors in Overcoming the Clinical Limitations of Ibrutinib. European Journal of Medicinal Chemistry, 229, Article ID: 114009. [Google Scholar] [CrossRef] [PubMed]
[16] Badar, T., Astle, J., Kakar, I.K., et al. (2020) Clinical Activity of Ibrutinib in Classical Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation Is Independent of Tumor BTK Expression. British Journal of Haematology, 190, e98-e101. [Google Scholar] [CrossRef] [PubMed]
[17] Szklener, K., Michalski, A., Żak, K., et al. (2022) Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Fu-ture Directions. Cells, 11, 1338. [Google Scholar] [CrossRef] [PubMed]
[18] 张燕芳, 朱晨影, 康媛源, 等. 砷剂联合方案抗血液肿瘤的临床应用与研究进展[J]. 中国现代应用药学, 2023, 49(9): 1260-1269.
[19] Huang, Q., Wang, T., Xiong, Y., et al. (2022) Safety and Efficacy of Compound Huangdai Tablets Combined with All-Trans Retin-oic Acid for Treatment of Acute Promyelocytic Leukemia: Clinical Evidence and Potential Mechanisms. Chinese Herbal Medicines, 14, 154-165. [Google Scholar] [CrossRef] [PubMed]

为你推荐